Mixed dyslipidemia
Clinical trials for Mixed dyslipidemia explained in plain language.
Never miss a new study
Get alerted when new Mixed dyslipidemia trials appear
Sign up with your email to follow new studies for Mixed dyslipidemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple-Drug cocktail aims to reverse early heart disease
Disease control Not yet recruitingThis Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have neve…
Matched conditions: MIXED DYSLIPIDEMIA
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new RNA drug tame high blood fats?
Disease control Not yet recruitingThis trial tests whether EDP167, an experimental RNA drug, can safely lower triglycerides and other harmful fats in the blood of adults with mixed dyslipidemia. Participants receive one of three doses of EDP167 or a placebo as an injection every 12 weeks, alongside their usual st…
Matched conditions: MIXED DYSLIPIDEMIA
Phase 2 • Sponsor: Eddingpharm (Zhuhai) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New Omega-3 pill could boost heart health better than standard fish oil
Disease control Not yet recruitingThis study tests whether a new omega-3 supplement called Ruby-O, made from phospholipids, raises omega-3 levels in the blood more effectively than standard omega-3 supplements. About 105 adults with mixed dyslipidemia (abnormal blood fats) who are already on statin therapy will t…
Matched conditions: MIXED DYSLIPIDEMIA
Sponsor: Fundación del Caribe para la Investigación Biomédica • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New cholesterol drug candidate enters early human testing
Disease control Not yet recruitingThis early-stage trial will test a new drug formulation (AD-117) for mixed dyslipidemia, a condition involving high cholesterol and triglycerides. Sixty healthy adults will receive a single dose of either the new or a reference formulation to compare how the body processes each. …
Matched conditions: MIXED DYSLIPIDEMIA
Phase 1 • Sponsor: Addpharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC